Psychomotor developmental effects of prenatal exposure to psychotropic drugs: a study in EFEMERIS database.
Little is known about neurodevelopment of children exposed to psychotropic drugs during pregnancy. The purpose of this study was to evaluate the effects of prenatal exposure to psychotropic drugs on psychomotor development in children. This observational study used the EFEMERIS database. The database records the drugs prescribed and delivered during pregnancy and the resulting outcomes. Neurodevelopment at nine and 24 months of children born to women exposed to psychotropic drugs (anxiolytics, antidepressants, neuroleptics and anti-epileptics) during the second and/or third trimesters of pregnancy was compared to children who were not exposed to these drugs. Psychomotor development of 493 children (1.5%) exposed to psychotropic drugs during pregnancy was compared to 32 303 unexposed children. Exposure to psychotropic drugs during pregnancy was associated with an increased risk of abnormal motor development at 9 months (OR = 1.3 [1.1-2.2]) and abnormal motor and mental development at 24 months (OR = 4.8 [2.1-11.0] and OR = 2.3 [1.05-4.9]). Increased risk was observed in children born to women exposed to anti-epileptic drugs, neuroleptics or antidepressants during pregnancy. This study found a higher rate of deviation from the normal developmental milestones in children born to women exposed to psychotropic drugs during pregnancy and more particularly antidepressants, neuroleptics and anti-epileptics.
Service de Pharmacologie Clinique, CHU de Toulouse, Inserm 1027, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France.
Caroline
C
Hurault-Delarue
Service de Pharmacologie Clinique, CHU de Toulouse, Inserm 1027, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France.
Christine
C
Damase-Michel
Caisse Primaire d'Assurance Maladie de la Haute-Garonne, 3 Boulevard du Professeur Léopold Escande, 31500, Toulouse, France.
Laurent
L
Finotto
Protection Maternelle et Infantile, Conseil Général, 1 Boulevard de la Marquette, 31090, Toulouse, France.
Claudine
C
Guitard
Centre de diagnostic anténatal, CHU de Toulouse, Hôpital Paule de Viguier, 330 avenue de Grande Bretagne - TSA, 70034 - 31059, Toulouse, France.
Christophe
C
Vayssière
Service de Pharmacologie Clinique, CHU de Toulouse, Inserm 1027, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France.
Jean-Louis
JL
Montastruc
Service de Pharmacologie Clinique, CHU de Toulouse, Inserm 1027, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France.
François
F
Montastruc
Service de Pharmacologie Clinique, CHU de Toulouse, Inserm 1027, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France. isabelle.lacroix@univ-tlse3.fr.
Isabelle
I
Lacroix
D002675:Child, Preschool; D016208:Databases, Factual / Q000639:trends*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011247:Pregnancy; D011297:Prenatal Exposure Delayed Effects / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D011596:Psychomotor Disorders / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology*; D011619:Psychotropic Drugs / Q000009:adverse effects*
D011619:Psychotropic Drugs
EFEMERIS database; pregnancy; psychomotor development; psychotropic drugs